CDS ranked as a Major Contender in the 2023 PEAK Matrix® Assessment
Reno, NV, November 11, 2022 – Crucial Data Solutions (CDS), a provider of innovative low-code/no-code technologies to advance clinical research, is pleased to announce they have been positioned as a Major Contender in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix®. Everest Group, an advisory and research firm that advises business leaders on next generation global services initiative, conducted an evaluation of the Life Sciences Decentralized Clinical Trial Platforms market focused on gauging the capabilities of DCT platform providers. The key objective of the research is to assess and profile the strategy & capabilities of DCT focused platform providers.
CDS’ TrialKit platform was assessed on its market impact and capabilities of its technology products that operationalize DCTs, including ePRO/eCOA, eConsent, wearable technology with BYOD integration, remote patient monitoring, televisits, real-world data (RWD) collection and analysis, enterprise-wide scalability and more. Through an extensive assessment and client interviews, Everest Group positioned CDS and their TrialKit platform as a Major Contender.
CDS has been supporting decentralized and hybrid studies, in addition to traditional clinical trials, since it first introduced the TrialKit mobile app in downloadable iOS and Android versions in 2017. TrialKit’s combined web interface and integrated mobile applications make it the industry’s first, most adaptable and affordable end-to-end eClinical platform which delivers unprecedented value and self-service configurability, allowing end users to design, deploy and manage any type, size or format of study in a SaaS, cloud environment.
Earlier this year, CDS released TrialKit Engage, a calendaring and video conferencing solution to enable virtual visits in decentralized and hybrid studies. Integrated with the rest of the TrialKit platform, this feature rounded out CDS’ comprehensive offerings for DCTs.
About Crucial Data Solutions
Founded in 2010, Crucial Data Solutions (CDS) provides the most innovative low-code/no-code data and clinical trial management technology on the market today. TrialKit, our cloud-based platform available via both a web and native mobile app, enables end-to-end clinical trial management for medical device, diagnostics, digital therapeutics, and biotechnology companies of all sizes. Design and deploy validated studies in days not weeks using our intuitive study builder that requires no programming. Over 10,000 global users have leveraged the flexibility of TrialKit to deploy over 7,000 studies across all phases of development, including Verily (a subsidiary of Alphabet), ICON GPHS, FUEL Studios, Catalyst Clinical Research, SISCAPA Assay Technologies, CDx Diagnostics, and Optinose, and many more.